Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMD-RX5 for psychological distress in adults with chronic pain
ACTRN12622001319763Phase 3Suspended
- Sponsor
- Emyria Ltd
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of EMD-RX5 in distress (4 arms), sponsored by Emyria Ltd. Primary endpoint: Change in DASS-21 anxiety score at Week 4. Started Jan 2023; status: suspended.
02
Drugs
EMD-RX5
03
Conditions
distress
Beyond the preview
Go deeper on ACTRN12622001319763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001319763.